ইউরোপীয় ইউনিয়ন - চেক - EMA (European Medicines Agency)

cis bio international - yttrium (90y) chloride - radionuklidové zobrazování - diagnostické radiofarmaka - k použití pouze pro radioaktivní značení dopravce molekul, které byly speciálně vyvinuty a povoleny pro radioaktivní značení tímto radionuklidem. radiopharmaceutical precursor - not intended for direct application to patients.

ইউরোপীয় ইউনিয়ন - চেক - EMA (European Medicines Agency)

gilead sciences ireland uc - bictegravir, emtricitabin, tenofovir alafenamide, fumarát - hiv infekce - antivirotika pro systémové použití - biktarvy is indicated for the treatment of human immunodeficiency virus 1 (hiv 1) infection in adults and paediatric patients at least 2 years of age and weighing at least 14 kg i without present or past evidence of viral resistance to the integrase inhibitor class, emtricitabine or tenofovir. (viz část 5.

ইউরোপীয় ইউনিয়ন - চেক - EMA (European Medicines Agency)

viiv healthcare b.v. - dolutegravir sodíku, rilpivirin-hydrochlorid - hiv infekce - antivirotika pro systémové použití - juluca je indikován k léčbě lidské imunodeficience typu 1 (hiv-1) infekce u dospělých, kteří jsou virologická léčba-potlačena (hiv-1 rna.

ইউরোপীয় ইউনিয়ন - চেক - EMA (European Medicines Agency)

viiv healthcare b.v. - dolutegravir sodíku, lamivudin - hiv infekce - antivirotika pro systémové použití - dovato je indikován k léčbě lidské imunodeficience typu 1 (hiv-1) infekce u dospělých a dospívajících nad 12 let věku o hmotnosti alespoň 40 kg, s žádné známé nebo podezření na rezistenci na inhibitory integrázy třídy, nebo lamivudinem.

ইউরোপীয় ইউনিয়ন - চেক - EMA (European Medicines Agency)

accord healthcare s.l.u. - doxorubicin hydrochloride, liposomal - ovarian neoplasms; sarcoma, kaposi; multiple myeloma - doxorubicin - zolsketil pegylated liposomal is a medicine used to treat the following types of cancer in adults:• breast cancer that has spread to other parts of the body in patients at risk of heart problems. zolsketil pegylated liposomal is used on its own for this disease;• advanced ovarian cancer in women whose previous treatment including a platinum-based cancer medicine has stopped working;• multiple myeloma (a cancer of the white blood cells in the bone marrow), in patients with progressive disease who have received at least one other treatment in the past and have already had, or are unsuitable for, a bone marrow transplantation. zolsketil pegylated liposomal is used in combination with bortezomib (another cancer medicine);• kaposi’s sarcoma in patients with aids who have a very damaged immune system. kaposi’s sarcoma is a cancer that causes abnormal tissue to grow under the skin, on moist body surfaces or on internal organs. zolsketil pegylated liposomal contains the active substance doxorubicin and is a ‘hybrid medicine’. this means that it is similar to a ‘reference medicine’ containing the same active substance called adriamycin. however, in zolsketil pegylated liposomal the active substance is enclosed in tiny fatty spheres called liposomes, whereas this is not the case for adriamycin.

ইউরোপীয় ইউনিয়ন - চেক - EMA (European Medicines Agency)

yes pharmaceutical development services gmbh - hydrochlorid doxorubicinu - breast neoplasms; ovarian neoplasms; multiple myeloma; sarcoma, kaposi - antineoplastická činidla - celdoxome pegylated liposomal is indicated in adults:as monotherapy for patients with metastatic breast cancer, where there is an increased cardiac risk. or treatment of advanced ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen. in combination with bortezomib for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplant. for treatment of aids-related kaposi’s sarcoma (ks) in patients with low cd4 counts (< 200 cd4 lymphocytes/mm3) and extensive mucocutaneous or visceral disease. celdoxome pegylated liposomal may be used as first-line systemic chemotherapy, or as second line chemotherapy in aids-ks patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and standard doxorubicin (or other anthracycline).

চেক প্রজাতন্ত্র - চেক - SUKL (Státní ústav pro kontrolu léčiv)

almirall hermal gmbh, reinbek array - 1680 fluoruracil; 1274 kyselina salicylovÁ - kožní roztok - 5mg/g+100mg/g - fluoruracil, kombinace

চেক প্রজাতন্ত্র - চেক - SUKL (Státní ústav pro kontrolu léčiv)

herbacos recordati s.r.o., pardubice array - 12 kyselina acetylsalicylovÁ; 102 kyselina askorbovÁ - Šumivá tableta - 320mg/200mg - kyselina acetylsalicylovÁ, kombinace kromĚ psycholeptik

চেক প্রজাতন্ত্র - চেক - SUKL (Státní ústav pro kontrolu léčiv)

lek pharmaceuticals d.d., ljubljana array - 11679 sodnÁ sŮl amoxicilinu; 5491 kalium-klavulanÁt - prášek pro injekční/infuzní roztok - 1000mg/200mg - amoxicilin a inhibitor beta-laktamasy

চেক প্রজাতন্ত্র - চেক - SUKL (Státní ústav pro kontrolu léčiv)

lek pharmaceuticals d.d., ljubljana array - 11679 sodnÁ sŮl amoxicilinu; 5491 kalium-klavulanÁt - prášek pro injekční/infuzní roztok - 500mg/100mg - amoxicilin a inhibitor beta-laktamasy